Treatment Intensification in Type 2 Diabetes: A Real-World Study of 2-OAD Regimens, GLP-1 RAs, or Basal Insulin
Open Access
- 19 April 2018
- journal article
- research article
- Published by Springer Science and Business Media LLC in Diabetes Therapy
- Vol. 9 (3), 1169-1184
- https://doi.org/10.1007/s13300-018-0429-x
Abstract
Introduction Treatment guidelines recommend a stepwise approach to glycemia management in patients with type 2 diabetes (T2D), but this may result in uncontrolled glycated hemoglobin A1c (HbA1c) between steps. This retrospective analysis compared clinical and economic outcomes among patients with uncontrolled T2D initiating two oral antidiabetes drugs (OADs), glucagon-like peptide-1 receptor agonists (GLP-1 RAs), or basal insulin in a real-world setting. Methods Adults with T2D on OAD monotherapy were identified in the MarketScan claims database (2007–2014). Those initiating two OADs (simultaneously or sequentially), GLP-1 RAs, or basal insulin were selected (date of initiation was termed the ‘index date’); patients were required to have HbA1c > 7.0% in the 6 months pre-index date. HbA1c was compared from 6 months pre- to 1-year post-index. Annual all-cause healthcare utilization and costs were reported over the 1-year follow-up period. Results Data for 6054 patients were analyzed (2-OAD, n = 4442; GLP-1 RA, n = 361; basal insulin, n = 1251). Baseline HbA1c was high in all cohorts, but highest in the basal-insulin cohort. Treatment initiation resulted in reductions in HbA1c in all cohorts, which was generally maintained throughout the follow-up period. Average HbA1c reductions from the 6 months pre- to 1 year post-index date were −1.2% for GLP-1 RA, −1.6% for OADs, and −1.8% for basal insulin. HbA1c < 7.0% at 1 year occurred in 32.6%, 47.5%, and 41.1% of patients, respectively. Annual healthcare costs (mean [SD]) were lowest for OAD (US$10,074 [$22,276]) followed by GLP-1 RA (US$14,052 [$23,829]) and basal insulin (US$18,813 [$37,332]). Conclusion Despite robust HbA1c lowering following treatment initiation, many patients did not achieve HbA1c < 7.0%. Basal insulin, generally prescribed for patients with high baseline HbA1c, was associated with a large reduction in HbA1c and with higher costs. Therapy intensification at an appropriate time could lead to clinical and economic benefits and should be investigated further. Funding Sanofi U.S., Inc.Keywords
Funding Information
- Sanofi
This publication has 28 references indexed in Scilit:
- The INITIATOR study: pilot data on real-world clinical and economic outcomes in US patients with type 2 diabetes initiating injectable therapy.Advances in Therapy, 2013
- Clinical Inertia in People With Type 2 DiabetesDiabetes Care, 2013
- The Prevalence of Meeting A1C, Blood Pressure, and LDL Goals Among People With Diabetes, 1988–2010Diabetes Care, 2013
- Clinical Impact of Initiating Insulin Glargine Therapy with Disposable Pen Versus Vial in Patients with Type 2 Diabetes Mellitus in a Managed Care SettingEndocrine Practice, 2011
- Addressing barriers to initiation of insulin in patients with type 2 diabetesPrimary Care Diabetes, 2010
- Administrative and Claims Records as Sources of Health Care Cost DataMedical Care, 2009
- Patient non-adherence and healthcare-provider inertia are clinical myopiaDiabetes & Metabolism, 2008
- Delay Of Insulin Addition To Oral Combination Therapy Despite Inadequate Glycemic ControlJournal of General Internal Medicine, 2007
- Clinical inertia in the management of Type 2 diabetes metabolic risk factorsDiabetic Medicine, 2004
- Clinical InertiaAnnals of Internal Medicine, 2001